Skip to main content
. 2018 May 29;9(41):26328–26341. doi: 10.18632/oncotarget.25242

Figure 2.

Figure 2

(A) A2780 (cisplatin-sensitive) cells show enhanced Ad-mediated reduction of cell viability with escalating dose of cisplatin, whereas (B) A2780/cp70 (cisplatin-resistant) cells show reduced Ad-mediated reduction in cell viability with escalating dose of cisplatin. Cells were infected with Ad5WT (replication-competent), dl24 (oncolytic) and control Ad (replication-deficient) at an MOI of 10 and treated with escalating doses of cisplatin (0–20 µM). Cell viability was measured by MTS assay at 72 h post-infection. Cell viability was calculated as a percentage of uninfected cells (control). Data was corrected for background absorbance from the incubation media. Data is expressed as the mean ± SEM. Experiments were performed in triplicate.